Phase III results show Roche ' s subcutaneous formulation of Tecentriq is comparable to intravenous Tecentriq and delivered in minutes

Administered under the skin, the subcutaneous formulation reduces time spent receiving treatment to approx. seven minutes, compared with 30-60 minutes for IV infusion1Roche has submitted data from the IMscin001 study to health authorities, seeking approval for the subcutaneous option across all approved indications of IVTecentriq  If approved,Tecentriq would be Roche ’s fourth subcutaneous cancer therapy,2-4 helping to improve the treatment experience for patients. In addition, it could save resources for healthcare systems5-10Basel, 1 December 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new pivotal data from the Phase III IMscin001 study, evaluating the investigational subcutaneous formulation of Tecentriq ® (atezolizumab), a cancer immunotherapy approved for various tumour types.1 Data showed comparable exposure (levels of the molecule in the blood) and similar safety and efficacy for Tecentriq, when administered subcutaneously (injected under the skin), compared to standard IV infusion, in people with previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC).The data will be presented in a mini-oral abstract session at 09:55 CET on Thursday 8 December, at the ESMO Immuno-Oncology Congress 2022 (Abstract #61MO).11If approved by health authorities, Roche aims to bring this innovation to patients who may benefit from treatment with Tecentriq across multiple tumour types. Data from IMscin001 have been submitted to health authoritie...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news